Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more
Kolon Life Science Inc - Asset Resilience Ratio
Kolon Life Science Inc (102940) has an Asset Resilience Ratio of 1.22% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Kolon Life Science Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Kolon Life Science Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.33 Billion | 1.22% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩7.33 Billion | 1.22% |
Asset Resilience Insights
- Limited Liquidity: Kolon Life Science Inc maintains only 1.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Kolon Life Science Inc Industry Peers by Asset Resilience Ratio
Compare Kolon Life Science Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for Kolon Life Science Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Kolon Life Science Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.96% | ₩12.42 Billion | ₩419.56 Billion | +0.54pp |
| 2023-12-31 | 2.42% | ₩7.48 Billion | ₩309.44 Billion | +0.39pp |
| 2022-12-31 | 2.03% | ₩6.37 Billion | ₩314.12 Billion | -9.87pp |
| 2021-12-31 | 11.89% | ₩27.91 Billion | ₩234.66 Billion | +5.84pp |
| 2020-12-31 | 6.05% | ₩15.03 Billion | ₩248.34 Billion | -1.46pp |
| 2019-12-31 | 7.51% | ₩20.91 Billion | ₩278.29 Billion | +1.41pp |
| 2018-12-31 | 6.10% | ₩37.77 Billion | ₩618.90 Billion | -4.89pp |
| 2017-12-31 | 11.00% | ₩78.83 Billion | ₩716.80 Billion | -27.88pp |
| 2016-12-31 | 38.88% | ₩137.85 Billion | ₩354.57 Billion | -- |